4.7 Article

Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2012.04.014

关键词

TENOR; severe or difficult-to-treat asthma; asthma control; asthma exacerbations; burden; medication; quality of life; allergy; IgE

资金

  1. Genentech
  2. AstraZeneca
  3. GlaxoSmithKline
  4. Novartis
  5. Sunovion
  6. Merck-Schering
  7. Alcon
  8. Aerocrine
  9. Merck and Co.
  10. Canadian Institutes of Health Research
  11. Boehringer-Ingelheim
  12. Schering-Plough
  13. National Institutes of Health/National Heart, Lung, and Blood Institute
  14. National Heart, Lung, and Blood Institute's Childhood Asthma Research and Education (CARE)
  15. National Institutes of Health/National Heart, Lung, and Blood Institute's Asthma Clinical Research Network (ACRN)
  16. National Institutes of Health/National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium (ICAC)
  17. National Institute of Environmental Health Sciences/Environmental Protection Agency's Childhood Environmental Health Center

向作者/读者索取更多资源

Patients with severe or difficult-to-treat asthma are an understudied population but account for considerable asthma morbidity, mortality, and costs. The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study was a large, 3-year, multicenter, observational cohort study of 4756 patients (n = 3489 adults >= 18 years of age, n = 497 adolescents 13-17 years of age, and n = 770 children 6-12 years of age) with severe or difficult-to-treat asthma. TENOR's primary objective was to characterize the natural history of disease in this cohort. Data assessed semiannually and annually included demographics, medical history, comorbidities, asthma control, asthma-related health care use, medication use, lung function, IgE levels, self-reported asthma triggers, and asthma-related quality of life. We highlight the key findings and clinical implications from more than 25 peer-reviewed TENOR publications. Regardless of age, patients with severe or difficult-to-treat asthma demonstrated high rates of health care use and substantial asthma burden despite receiving multiple long-term controller medications. Recent exacerbation history was the strongest predictor of future asthma exacerbations. Uncontrolled asthma, as defined by the 2007 National Heart, Lung, and Blood Institute guidelines' impairment domain, was highly prevalent and predictive of future asthma exacerbations; this assessment can be used to identify high-risk patients. IgE and allergen sensitization played a role in the majority of severe or difficult-to-treat asthmatic patients. (J Allergy Clin Immunol 2012;130:332-42.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据